BAT IT: Banked Anti-SARS Cov-2 T Cell Infusions for Treatment of COVID 19
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 4
- 试验地点
- 1
- 主要终点
- Randomized Trial: Rate of Clinical Response as assessed by the World Health Organization (WHO) Ordinal Scale [7 days post-randomization or hospital discharge]
研究概览
简要总结
This is a dose-finding safety trial followed by a randomized pilot trial comparing administration of SARS-CoV2-specific T cells (SARS-CoVSTs) to standard of care treatment in hospitalized patients with COVID19 who are at high risk of requiring mechanical ventilation.
The SARS-CoVSTs lines have been made at Baylor College of Medicine from healthy donors who have made a full recovery from COVID19. These cell lines were frozen for later use and will be thawed and used to treat patients who meet the eligibility criteria.
详细描述
The first part of this study is to identify the maximum tolerated dose (MTD) of allogeneic SARS-CoV2-specific T cells (SARS-CoVSTs) for patients with COVID19 with high risk of progression to mechanical ventilation.
The 3 dose levels (DL) are:
DL1: 1x10^7 cells (flat dose) DL2: 2x10^7 cells (flat dose) DL3: 4x10^7 cells (flat dose)
Enrollment to the dose escalation phase will be staggered. The first patient enrolled on each of the 3 dose levels (DL1, DL2 and DL3) will have to complete the 14-day toxicity monitoring window prior to enrollment of the next patients. Prior to dose escalation, all patients at a particular dose level should have completed the minimum 14-day toxicity monitoring window before enrolling to a higher dose level.
After the dose finding phase is complete and the MTD established, a randomized trial will be conducted. Patient will be randomized 1:1 using the permuted block method with a block size of 4 (2 in the treatment arm and 2 in the control arm) to receive treatment with SARS-CoVSTs or routine treatment per institutional standards.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •SARS-CoV-2 infection confirmed by polymerase chain reaction assay (PCR) from a nasopharyngeal swab or other accepted specimen type. (If testing was performed ≥ 5 days before enrollment, this must be repeated and accept only if positive again). Date of COVID test must be ≤ 5 days prior to infusion.
- •Currently hospitalized adult patient (≥ 18 years of age) requiring medical care for COVID19
- •Peripheral oxygen saturation (SpO2) ≥ 92% on room air
- •Hgb ≥ 7.0 gm/dl
- •Negative pregnancy test (if applicable)
- •Patient or parent/guardian capable of providing informed consent (may be obtained electronically)
- •Evidence of pulmonary infiltrates on chest imaging. Any chest imaging findings which would be consistent with COVID19 would qualify (Eg: ground glass opacities, multifocal infiltrates etc.)
- •High risk of requiring mechanical ventilation as defined by at least two of the following:
- •Age ≥ 60 years of age
- •Age ≥ 75 years of age (counts as meeting two criteria)
- •Hypertension (HTN)
- •Chronic cardiovascular disease other than HTN (eg: Coronary artery disease, congestive heart failure or cardiomyopathies).
- •Diabetes Mellitus
- •Obesity (BMI ≥ 30)
- •Obesity (BMI ≥ 40, counts as meeting two criteria)
- •Active cancer diagnosis or ongoing (within 3 months) cytotoxic chemo/ radio-therapy for a cancer
- •Post-hematopoeitic stem cell or solid organ transplantation status
- •Immunodeficiency states including HIV infection on antiretroviral therapy (except those listed as
排除标准
- •#1, #7 and #10) as determined by the treating physician (eg: receiving immunosuppressive therapy like rituximab or congenital immunodeficiency syndromes, prior treatment with chemotherapy greater than 3 months ago but per investigators discretion could have lingering effects on the immune system, eg: chemotherapy regimens for lymphomas, ALL or AML etc.)
- •Chronic obstructive pulmonary disease (COPD)
- •Current everyday smoker
- •Chronic kidney disease (eGFR < 30 mL/min/1.73 m2 )
- •Bronchial asthma (on active treatment prior to admission, eg. Use of rescue inhalers or inhaled corticosteroids or other treatments to prevent/treat attacks).
- •Exclusion Criteria
- •Received Anti-thymocyte globulin (ATG), Campath or other T cell immunosuppressive monoclonal antibodies in the 28 days prior to screening for enrollment
- •Requiring mechanical ventilation at time of T cell infusion
- •Alanine aminotransferase or aspartate aminotransferase greater than 5 x upper limit of normal
- •If previously undergone an allogeneic hematopoietic stem cell transplant and have evidence of active acute GVHD greater than or equal to grade 2
- •Uncontrolled relapse of malignancy
- •Requiring vasopressors
- •Known history of autoimmune disease except prior thyroiditis
- •Is not suitable at the discretion of the treating physician
- •Patients on greater than 6mg/day of dexamethasone (IV) or equivalent
- •Greater than grade 1 CRS per American Society for Transplantation and Cellular Therapy (ASTCT) criteria
- •Patients should not be enrolled on any other interventional clinical trials for COVID
- •Patients may receive routine care for COVID19 per institutional standards (including antivirals such as remdesivir or other FDA-EUA approved products and thromboprophylaxis).
研究组 & 干预措施
Dose Finding Phase
This phase is designed to evaluate the maximum tolerated dose (MTD) of partially HLA-matched SARS-CoVSTs administered to hospitalized COVID19 patients with high risk of progression to mechanical ventilation.
The dose finding phase is a standard 3+3 safety study design. The 3 dose levels are:
DL1: 1x10^7 cells (flat dose) DL2: 2x10^7 cells (flat dose) DL3: 4x10^7 cells (flat dose)
干预措施: Dose Finding Phase (MTD) (Biological)
Randomized Pilot - SARS-CoVSTs
Partially HLA-matched Virus Specific T cells (VSTs) will be given by intravenous injection.
干预措施: Partially HLA-matched SARS-CoVSTs (Biological)
Randomized Pilot - Routine Care
Hospitalized patients with COVID-19 will be treated per current institutional guidelines.
干预措施: Routine care (no SARS-CoVSTs) (Other)
结局指标
主要结局
Randomized Trial: Rate of Clinical Response as assessed by the World Health Organization (WHO) Ordinal Scale [7 days post-randomization or hospital discharge]
时间窗: 7 Days post-randomization or at time of hospital discharge
Clinical Response rate is defined as the proportion of subjects reporting an increase in 2 or more points on the WHO Ordinal Scale. \[Scored on a scale from 0 to 8; where 0 = Uninfected and 8 =Dead\] or until patient is discharged.
Dose Escalation Phase: Rate of Dose Limiting Toxicities by CTCAE 5.0 [14 days post infusion]
时间窗: 14 days post infusion
Defined as the proportion of subjects with toxicity including the type, severity, time of onset, time of resolution, and the probable association with study treatment. A dose limiting toxicity is defined as any acute GvHD (\> grade 2), grade ≥3 CRS or ICANS, grade ≥3 hematologic toxicity or grade ≥3 non-hematologic adverse events related to the T cell product within 14 days of the VST infusion and that are not due to pre-existing conditions as defined by the NCI Common Terminology Criteria for Adverse Events (CTCAE), Version 5.
次要结局
- Randomized Trial: Rate of Treatment-related adverse events (tAE) by CTCAE 5.0 [14 days post-randomization](14 days post-randomization)
研究者
Premal Lulla
Assistant Professor
Baylor College of Medicine